Marketdash
Back to News

Wall Street's Monday Morning Calls: Amazon Gets a Boost While Analyst Ratings Shake Up 10 Major Stocks

MarketDash Editorial Team
7 days ago
Top Wall Street analysts shuffled their ratings and price targets across multiple sectors Monday, with Amazon drawing an upgraded target that implies significant upside. The day's calls included both upgrades and downgrades spanning telecommunications, biotech, retail, and industrial sectors.

Wall Street's top analysts kicked off the week with a flurry of rating changes and price target adjustments across a diverse range of companies. The moves reflect shifting expectations about everything from e-commerce growth to biotech trajectories and infrastructure investments.

Here's the complete rundown of Monday's notable analyst calls:

Tech and E-Commerce

Amazon.com Inc. (AMZN) caught a bullish update from Oppenheimer, which raised its price target from $290 to $305 while maintaining an Outperform rating. Analyst Jason Helfstein's new target implies potential upside of around 31% from Amazon's Friday closing price of $233.22. The adjustment suggests growing confidence in the company's business momentum heading into the new year.

Life Sciences and Biotech

The biotech sector saw several significant moves. PTC Therapeutics, Inc. (PTCT) received a mixed signal from RBC Capital, which lifted its price target from $82 to $91 but downgraded the stock from Outperform to Sector Perform. Analyst Brian Abrahams appears to see the valuation catching up to expectations, with shares closing Friday at $85.99.

Insmed Incorporated (INSM) scored a substantial vote of confidence from Mizuho, which boosted its price target from $196 to $256. Analyst Graig Suvannavejh maintained an Outperform rating on the stock, which settled at $207.77 on Friday.

Prothena Corporation plc (PRTA) saw Citizens nearly double its price target from $11 to $19. Analyst Jason Butler kept a Market Outperform rating on the biotech, even as shares closed Friday at $10.75, suggesting significant upside potential if the company hits its milestones.

Thermo Fisher Scientific Inc. (TMO) received one of the day's most bullish calls, with HSBC upgrading the stock from Hold to Buy while raising its price target from $550 to $670. Analyst Sidharth Sahoo's upgrade comes as the life sciences tools company's shares settled at $590.76 on Friday.

Industrials and Infrastructure

Argan Inc. (AGX) got a price target increase from JP Morgan, moving from $315 to $370, but analyst Michael Fairbanks simultaneously downgraded the stock from Overweight to Neutral. With shares closing at $395.20 on Friday, the industrial construction company is already trading well above the new target, explaining the more cautious stance.

Old Dominion Freight Line, Inc. (ODFL) received a modest price target trim from BMO Capital, dropping from $172 to $170, but analyst Fadi Chamoun upgraded the stock from Market Perform to Outperform. The freight carrier closed Friday at $135.29, leaving room for potential appreciation in Chamoun's view.

Telecommunications

Crown Castle Inc. (CCI) faced a double dose of caution from Barclays, which lowered both its rating and price target. Analyst Brendan Lynch downgraded the cell tower operator from Overweight to Equal-Weight while cutting the price target from $104 to $101. Shares closed at $91.28 on Friday.

Gaming and Entertainment

Light & Wonder, Inc. (LNW) received an enthusiastic update from Benchmark, which raised its price target from $90 to $110 while maintaining a Buy rating. Analyst Mike Hickey's bullish stance comes as the gaming company's shares closed at $86.22 on Friday.

Retail

Target Corporation (TGT) saw Argus Research trim its price target from $135 to $125, though analyst Christopher Graja maintained a Buy rating. The retail giant's shares closed at $90.62 on Friday, reflecting ongoing challenges in the retail environment despite the analyst's constructive long-term view.

These rating changes reflect the constant recalibration happening on Wall Street as analysts digest earnings results, update financial models, and reassess their views on where various sectors and companies are headed. For investors, they provide a snapshot of how professional analysts are thinking about risk and reward across different corners of the market.

Back to News

Wall Street's Monday Morning Calls: Amazon Gets a Boost While Analyst Ratings Shake Up 10 Major Stocks

MarketDash Editorial Team
7 days ago
Top Wall Street analysts shuffled their ratings and price targets across multiple sectors Monday, with Amazon drawing an upgraded target that implies significant upside. The day's calls included both upgrades and downgrades spanning telecommunications, biotech, retail, and industrial sectors.

Wall Street's top analysts kicked off the week with a flurry of rating changes and price target adjustments across a diverse range of companies. The moves reflect shifting expectations about everything from e-commerce growth to biotech trajectories and infrastructure investments.

Here's the complete rundown of Monday's notable analyst calls:

Tech and E-Commerce

Amazon.com Inc. (AMZN) caught a bullish update from Oppenheimer, which raised its price target from $290 to $305 while maintaining an Outperform rating. Analyst Jason Helfstein's new target implies potential upside of around 31% from Amazon's Friday closing price of $233.22. The adjustment suggests growing confidence in the company's business momentum heading into the new year.

Life Sciences and Biotech

The biotech sector saw several significant moves. PTC Therapeutics, Inc. (PTCT) received a mixed signal from RBC Capital, which lifted its price target from $82 to $91 but downgraded the stock from Outperform to Sector Perform. Analyst Brian Abrahams appears to see the valuation catching up to expectations, with shares closing Friday at $85.99.

Insmed Incorporated (INSM) scored a substantial vote of confidence from Mizuho, which boosted its price target from $196 to $256. Analyst Graig Suvannavejh maintained an Outperform rating on the stock, which settled at $207.77 on Friday.

Prothena Corporation plc (PRTA) saw Citizens nearly double its price target from $11 to $19. Analyst Jason Butler kept a Market Outperform rating on the biotech, even as shares closed Friday at $10.75, suggesting significant upside potential if the company hits its milestones.

Thermo Fisher Scientific Inc. (TMO) received one of the day's most bullish calls, with HSBC upgrading the stock from Hold to Buy while raising its price target from $550 to $670. Analyst Sidharth Sahoo's upgrade comes as the life sciences tools company's shares settled at $590.76 on Friday.

Industrials and Infrastructure

Argan Inc. (AGX) got a price target increase from JP Morgan, moving from $315 to $370, but analyst Michael Fairbanks simultaneously downgraded the stock from Overweight to Neutral. With shares closing at $395.20 on Friday, the industrial construction company is already trading well above the new target, explaining the more cautious stance.

Old Dominion Freight Line, Inc. (ODFL) received a modest price target trim from BMO Capital, dropping from $172 to $170, but analyst Fadi Chamoun upgraded the stock from Market Perform to Outperform. The freight carrier closed Friday at $135.29, leaving room for potential appreciation in Chamoun's view.

Telecommunications

Crown Castle Inc. (CCI) faced a double dose of caution from Barclays, which lowered both its rating and price target. Analyst Brendan Lynch downgraded the cell tower operator from Overweight to Equal-Weight while cutting the price target from $104 to $101. Shares closed at $91.28 on Friday.

Gaming and Entertainment

Light & Wonder, Inc. (LNW) received an enthusiastic update from Benchmark, which raised its price target from $90 to $110 while maintaining a Buy rating. Analyst Mike Hickey's bullish stance comes as the gaming company's shares closed at $86.22 on Friday.

Retail

Target Corporation (TGT) saw Argus Research trim its price target from $135 to $125, though analyst Christopher Graja maintained a Buy rating. The retail giant's shares closed at $90.62 on Friday, reflecting ongoing challenges in the retail environment despite the analyst's constructive long-term view.

These rating changes reflect the constant recalibration happening on Wall Street as analysts digest earnings results, update financial models, and reassess their views on where various sectors and companies are headed. For investors, they provide a snapshot of how professional analysts are thinking about risk and reward across different corners of the market.